Treatment Decisions in Multiple Myeloma
Clinicians must understand the treatment evolution and guidelines for when to administer two-, three-, or four drug regimens as initial or subsequent therapy in context of the patient's therapeutic and disease history. In addition, it is important for clinicians to educate patients about their different treatment options (e.g., administration and adverse events) and discuss patient preferences and individual circumstances that may affect treatment recommendations.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
How to Incorporate Immunotherapies in the Management of Multiple Myeloma
Education about individualizing treatment strategies will assist healthcare providers to make informed decisions about incorporating immunotherapies into treatment regimens. 
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Managing Cardiovascular Events in Multiple Myeloma
With careful risk assessment, monitoring, and prophylactic treatment, the cardiovascular adverse events associated with multiple myeloma (MM) treatments can be prevented or identified and managed at an early stage. To optimize the management of patients with multiple myeloma and cardiac comorbidities, it is important for clinicians to learn how to recognize these risks and implement appropriate management strategies.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Archived Monthly Oncology Tumor Boards: Management of Patients with Multiple Myeloma
In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines’ recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or multiple myeloma-specific adverse events.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Management of Relapsed/Refractory Multiple Myeloma
Understanding optimal sequencing for patients with relapsed/refractory multiple myeloma can be a challenge in clinical practice. A uniform treatment approach cannot be applied to all patients. Physicians and other care providers must understand the evolving therapeutic options in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies
While cytokine release syndrome and neurotoxicity are widely reported as the most common acute CAR T-cell toxicities, it is essential for providers to understand that CAR T-cell therapy may also result in other toxicities (such as infections, cytopenias, or B-cell aplasia), some of which could persist for months to years after infusion.
Category
  • Management of Immunotherapy-Related Toxicities
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers
Bispecific T-cell engagers are emerging as promising treatment options for patients with heavily pretreated multiple myeloma and B-cell lymphomas, especially for patients with disease relapse following CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with bispecific T-cell engager therapy.
Category
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies
A better understanding of the pathogenesis of hematologic malignancies has led to the identification of new cytogenetic and molecular markers that distinguish between the various subtypes of hematologic malignancies. Informing hematologists and oncologists about the updated WHO5 classification and the new ICC will aid in the accurate diagnosis and development of a treatment plan to the specific subtype of hematologic malignancy.
Category
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma is a challenging disease state to treat and there are now numerous approved agents for this patient population. Clinicians would greatly benefit from additional education on the available agents and their place in therapy given the different modalities of treatment employed in relapsed/refractory disease.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification
Clinicians must understand the treatment evolution and guidelines for when to administer two-, three- or four- drug regimens as initial therapy in the context of the patient's therapeutic and disease history. Understanding how to individualize treatment will improve outcomes of patients with newly diagnosed MM.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation

Pages